Kangpu Biopharmaceuticals a clinical-stage company based in Shanghai, China, announced today that the Company has completed patient enrollment for the Phase IIa clinical trial of KPG-818 aimed at the treatment of systemic lupus erythematosus (SLE) in the US. The statement(s) made in this press release describing Kangpu's predictions, expectations and objectives may be forward-looking statements within the meaning of all applicable laws and regulations. These statements and expectations envisaged by the management are only estimates. Actual results may differ materially from such expectations due to risks, uncertainties and other factors, including, but not limited to, changes in regulatory and/or economic conditions, uncertain outcomes in the clinical studies, exposure to market risks, and other external and internal factors, which are beyond the control of Kangpu.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!